Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cortecs adopts radical measures following increasing losses and plummeting share prices

This article was originally published in Clinica

Executive Summary

Troubled UK biotechnology company Cortecs has announced a range of measures, including a strategy change, fundraising, a new name and a new chairman, aimed at revitalising its business. Over the past few years, the company has faced increasing losses and disappointing drug development results and seen its share price plummet from around 400p to just 16p. The company's share value fell 1p on the news. The announcement had little impact on the company's share price.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079879

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel